NCT00057343终止3 期
A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Biogen
- 入组人数
- 400
- 试验地点
- 66
- 主要终点
- Event-free survival
研究概览
简要总结
The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Summary of major inclusion and
排除标准
- •. Other Safety criteria will need to be met.
- •Inclusion Criteria:
- •Histologically confirmed, relapsed or refractory CD20+ follicular B-cell NHL within 12 months of Study Day 1 (without clinical evidence of transformation). NHL must require treatment as determined by an increase in overall tumor size. The presence of B symptoms, and/or the presence of masses which are causing ongoing clinical symptoms.
- •Bidimensionally measurable disease meeting the minimum requirement of at least 1 lesion >/= 2.0 cm in a single dimension.
- •No lymphoma therapy for 3 weeks prior to Study Day
- •Patients must be recovered from all toxicities associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy.
- •Signed IRB-approved informed consent.
- •Greater than 18 years of age.
- •Expected survival >/= 3 months.
- •WHO performance status of </=
- •Acceptable hematologic status, liver function, renal function, and pulmonary function.
- •Female patients who are not pregnant or lactating.
- •Men and women of reproductive potential who are following accepted birth control methods.
- •Exclusion Criteria:
- •Patients with impaired bone marrow reserve, which may be indicated by prior myeloablative therapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue.
- •Prior radioimmunotherapy, including the Zevalin regimen.
- •Prior immunotherapy, including Rituxan therapy within 6 months of Study Day
- •Rituxan-refractory (no response to most recent Rituxan-containing regimen, or TTP was < 6 months).
- •Presence of CNS lymphoma.
- •Patients with chronic lymphocytic leukemia (CLL).
- •Known history of HIV or AIDS.
- •Serious nonmalignant disease or infection
- •Major surgery, other than diagnostic surgery, within 4 weeks of Study Day
- •Patients who received investigational product within 4 weeks of Study Day 1 or patients who may experience long-term toxicity from a previous investigational therapy.
结局指标
主要结局
Event-free survival
次要结局
- partial response rate
- duration of response
- time to progression
- time-to-next anticancer therapy
- quality of life
- overall survival
- safety profile
- overall response rate
- complete response rate
- unconfirmed complete response rate
研究者
研究点 (66)
Loading locations...
相似试验
已完成
3 期
HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction TherapyHigh-Grade LymphomasNCT00866203Gruppo Italiano Studio Linfomi441
已完成
1 期
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaLymphoma, Non-HodgkinNCT05824585Dizal Pharmaceuticals17
Unknown
不适用
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenRelapsed or Refractory NeuroblastomaNCT02919046Sinobioway Cell Therapy Co., Ltd.22
已完成
1 期
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus InfectionOral Herpes SimplexNCT01308424Beech Tree Labs, Inc.171
Unknown
不适用
Study Evaluating the Efficacy and Safety With CAR-T for Liver CancerLiver NeoplasmsNCT02729493Sinobioway Cell Therapy Co., Ltd.25